Open Nav

Diffusion Pharmaceuticals Inc.

  • David Kalergis, Diffusion Pharmaceuticlas Inc.


  • Date:Thursday, October 18
  • Time:10:15 AM - 10:30 AM
  • Room:Elizabethan D
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Publicly Traded Company
  • Company Description/Mission Statement:Diffusion is a clinical stage biotechnology company. The company is currently enrolling patients in a Phase 3 trial in glioblastoma multiforme (GBM) brain cancer. Diffusion is also set to begin a Phase 2 in-ambulance trial in Stroke in partnership with UCLA.
  • Company
  • Company HQ City:Charlottesville
  • Company HQ Country:United States
  • Company HQ State:Virginia                        
  • Market Cap:~$20 million
  • Ticker:DFFN
  • Exchange:NASDAQ
  • CEO/Top Company Official:David Kalergis
  • Year Founded:2001
  • Main Therapeutic Focus:Oncology
  • Lead Product in Development :Trans Sodium Crocetinate (TSC)
  • Development Phase of Primary Product:Phase III
  • Number Of Unlicensed Products (For Which You Are Seeking Partners) :2
David Kalergis
Diffusion Pharmaceuticlas Inc.